Tyler Halverson1, Kannayiram Alagiakrishnan2. 1. Department of Medicine, Division of Psychiatry, University of Alberta, Edmonton, Alberta Canada. 2. Department of Medicine, Division of Geriatric Medicine, University of Alberta, Edmonton, Alberta, Canada.
Abstract
INTRODUCTION: As individuals age, the prevalence of neurocognitive and mental health disorders increases. Current biomedical treatments do not completely address the management of these conditions. Despite new pharmacological therapy the challenges of managing these diseases remain.There is increasing evidence that the Gut Microbiome (GM) and microbial dysbiosis contribute to some of the more prevalent mental health and neurocognitive disorders, such as depression, anxiety, obsessive-compulsive disorder (OCD), post-traumatic stress disorder (PTSD), schizophrenia, bipolar disorder (BP), and dementia as well as the behavioural and psychological symptoms of dementia (BPSD) through the microbiota-gut-brain axis. Methodology: Scoping review about the effect of gut microbiota on neurocognitive and mental health disorders. RESULTS: This scoping review found there is an evolving evidence of the involvement of the gut microbiota in the pathophysiology of neurocognitive and mental health disorders. This manuscript also discusses how the psychotropics used to treat these conditions may have an antimicrobial effect on GM, and the potential for new strategies of management with probiotics and faecal transplantation. CONCLUSIONS: This understanding can open up the need for a gut related approach in these disorders as well as unlock the door for the role of gut related microbiota management. KEY MESSAGES Challenges of managing mental health conditions remain in spite of new pharmacological therapy. Gut dysbiosis is seen in various mental health conditions. Various psychotropic medications can have an influence on the gut microbiota by their antimicrobial effect.
INTRODUCTION: As individuals age, the prevalence of neurocognitive and mental health disorders increases. Current biomedical treatments do not completely address the management of these conditions. Despite new pharmacological therapy the challenges of managing these diseases remain.There is increasing evidence that the Gut Microbiome (GM) and microbial dysbiosis contribute to some of the more prevalent mental health and neurocognitive disorders, such as depression, anxiety, obsessive-compulsive disorder (OCD), post-traumatic stress disorder (PTSD), schizophrenia, bipolar disorder (BP), and dementia as well as the behavioural and psychological symptoms of dementia (BPSD) through the microbiota-gut-brain axis. Methodology: Scoping review about the effect of gut microbiota on neurocognitive and mental health disorders. RESULTS: This scoping review found there is an evolving evidence of the involvement of the gut microbiota in the pathophysiology of neurocognitive and mental health disorders. This manuscript also discusses how the psychotropics used to treat these conditions may have an antimicrobial effect on GM, and the potential for new strategies of management with probiotics and faecal transplantation. CONCLUSIONS: This understanding can open up the need for a gut related approach in these disorders as well as unlock the door for the role of gut related microbiota management. KEY MESSAGES Challenges of managing mental health conditions remain in spite of new pharmacological therapy. Gut dysbiosis is seen in various mental health conditions. Various psychotropic medications can have an influence on the gut microbiota by their antimicrobial effect.
Entities:
Keywords:
Gut microbiota; antimicrobial activity; mental health
Authors: Nicholas M Vogt; Robert L Kerby; Kimberly A Dill-McFarland; Sandra J Harding; Andrew P Merluzzi; Sterling C Johnson; Cynthia M Carlsson; Sanjay Asthana; Henrik Zetterberg; Kaj Blennow; Barbara B Bendlin; Federico E Rey Journal: Sci Rep Date: 2017-10-19 Impact factor: 4.379
Authors: Adam J Walker; J Blair Price; Kristin Borreggine; Shari L Sutor; Andrea Gogos; Jane A McGillivray; Mark A Frye; Susannah J Tye Journal: Transl Psychiatry Date: 2019-03-15 Impact factor: 6.222
Authors: Samuel J Bowers; Keith C Summa; Robert S Thompson; Antonio González; Fernando Vargas; Christopher Olker; Peng Jiang; Christopher A Lowry; Pieter C Dorrestein; Rob Knight; Kenneth P Wright; Monika Fleshner; Fred W Turek; Martha H Vitaterna Journal: Front Neurosci Date: 2022-05-24 Impact factor: 5.152
Authors: Emily A Troyer; Jordan N Kohn; Gertrude Ecklu-Mensah; Gajender Aleti; David R Rosenberg; Suzi Hong Journal: Neurosci Biobehav Rev Date: 2021-02-24 Impact factor: 9.052
Authors: Yun-Han Wang; Viktor Wintzell; Jonas F Ludvigsson; Henrik Svanström; Björn Pasternak Journal: Clin Transl Sci Date: 2022-01-19 Impact factor: 4.438
Authors: Gael Urait Varela-Trinidad; Carolina Domínguez-Díaz; Karla Solórzano-Castanedo; Liliana Íñiguez-Gutiérrez; Teresita de Jesús Hernández-Flores; Mary Fafutis-Morris Journal: Microorganisms Date: 2022-07-14